May 2020- Orexo and Lyfebulb announced a partnership to help people struggling with alcohol and opioid use disorders in the times of the COVID-19 pandemic.
November 2019- Indivior launched a direct-to-consumer advertising campaign for informing people about the additional treatment for opioid use disorder (OUD), which involves the use of a drug called SUBLOCADE.
Author Credits: Radhika Gupta, Shivam Bhutani
Report ID: 4003
Published Date: May 01, 2023
Report Format: PDF, PPT
Frequently Asked Questions (FAQ)
The major factors driving the market growth are the increasing number of cases of opioid abuse and addictions among people worldwide and favorable reimbursements for smoking cessation therapy.
The market size of opioid dependence treatment is anticipated to attain a CAGR of 9% over the forecast period, i.e., 2023-2035.
Side effects of opioid use disorder drugs are estimated to hamper the market growth.
North America is estimated to create notable growth opportunities for market growth over the forecast period.
The major players in the market are Orexo AB, Indivior PLC, Titan Pharmaceuticals, Inc., Viatris Inc., Pfizer, Inc., and Others.
The company profiles are selected based on the revenues generated from the product segment, the geographical presence of the company which determines the revenue generating capacity as well as the new products being launched into the market by the company.
The market is segmented by drug class, sales channel, and region.
The hospital segment is anticipated to garner the largest market size by the end of 2035 and display significant growth opportunities.